Research and projectsList of all projects

List of all projects OVARIA

Duration Duration: 2012–2018

Contracting authority Contracting authority: Czech Society for Oncology

Terminated clinical registry of ovarian cancer patients who were treated with bevacizumab (Avastin®) and/or olaparib (Lynparza®).


The OVARIA registry was a non-interventional, post-authorisation database focused on the collection of epidemiological and clinical data on patients with ovarian cancer who were treated with bevacizumab (Avastin®) and/or olaparib (Lynparza®). The registry had been launched in September 2012 and provided a comprehensive overview of treatment of ovarian cancer patients and its results.

The main objective of the registry was to monitor ovarian cancer patients who were treated with bevacizumab and/or olaparib. The OVARIA project provided coherent and well-arranged information on the overall treatment of those patients, the potential sequence of targeted therapies, and the patients’ response to treatment.

Apart from providing epidemiological characteristics of breast cancer patients, the registry also enabled researchers to assess risk factors on patients’ survival and to analyse adverse effects. The registry was also used to make pharmacoeconomic assessments such as planning costs for cancer therapy.

The project had been initiated at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.

Primary objectives of the project:

  • monitoring the overall number of ovarian cancer patients in the Czech Republic treated with bevacizumab and/or olaparib,
  • assessment of safety of targeted therapy,
  • assessment of effectiveness of targeted therapies and of applied treatment regimens.

Secondary objectives of the project:

  • analysis of patients’ survival in relation to monitored clinical factors,
  • analysis of patient cohort treated with targeted therapies in relation to Czech reference population data.

Other important information:

  • Expert guarantor: Katarína Petráková, MD, PhD (Czech Society for Oncology)
  • Partners: 16 cancer centres in the Czech Republic (you can find more detailed information on the website of the OVARIA project)
  • Brief overview of results: you can find more detailed information on the website of the OVARIA project
OVARIA: clinical registry of ovarian cancer patients who have been treated with bevacizumab and/or olaparib

URL URL: http://ovaria.registry.cz


Back